Drugs / ACLOPROXALAP
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05443685 | Jan 2023 → Apr 2026 | Sjogren-Larsson syndrome | University of Nebraska | Completed | No outcome recorded |
| Phase 1/2 | NCT05487404 | Nov 2021 → May 2022 | poisoning | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary | ||||||
| Phase 2 | NCT06685692 | Nov 2024 → Jun 2025 | alcoholic hepatitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05717920 | Feb → Nov 2023 | atopic eczema | Aldeyra Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT05599815 | Jan → May 2023 | nephrotic syndrome | Aldeyra Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05392192 | Apr 2022 → Apr 2023 | — | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04908514 | May 2021 → Jan 2022 | psoriasis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04847544 | Mar → Oct 2021 | COVID-19 | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04728711 | Jan 2021 → Jan 2022 | allergic asthma | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-10-28 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules aldeyra.com ↗
Relative to baseline, statistically significant improvement was observed in clinically relevant objective markers of hepatic function and inflammation, including the Model for End-Stage Liver Disease (MELD) score (P=0.001), triglyceride levels (P<0.0001), and levels of C-Reactive Protein (P<0.0001). |
| 2024-01-04 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases aldeyra.com ↗
Broad-based normalization of the majority of abnormal metabolomic signatures was observed along with reduction in accumulation of fatty alcohols. |
| 2023-12-19 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis aldeyra.com ↗
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in patients with atopic dermatitis. |
| 2023-06-27 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough aldeyra.com ↗
The clinical trial demonstrated statistically significant reduction in cough frequency following administration of ADX ‑ 629 relative to placebo. |
| 2022-12-13 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial aldeyra.com ↗
Relative to placebo, ADX-629 reduced dermal flushing (P=0.0007), increased Romberg test balance time (P=0.02), and lowered levels of the ethanol RASP metabolite acetaldehyde (P=0.03) following acute exposure to alcohol. |
| 2022-03-29 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day aldeyra.com ↗
today will announce at its 2022 Research & Development Day that three clinical trials of ADX-629, a first-in-class orally administered RASP modulator, generated signs of pharmacodynamic and clinical activity consistent with broad-based reduction in pathologic inflammation. |
| 2020-09-09 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients aldeyra.com ↗
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial evaluating ADX-629, a novel orally available reactive aldehyde species (RASP) inhibitor, for the treatment of adult patients hospitalized for COVID-19. |
| 2020-04-14 | Aldeyra Therapeutics, Inc. | Results Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629 aldeyra.com ↗
ADX-629 was well-tolerated, and no treatment-related adverse events were observed in the trial. |
All press releases naming this drug 13 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACLOPROXALAP | ChEMBL registry synonym — accepted as the source's own label CHEMBL4994054 ↗ |
| Known as | ADX-629 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05392192 ↗ |
| Modality | Other / unclassified | “oral pharmacologic aldehyde trapping agent ADX-629” NCT05443685 ↗ |
| Route | Oral | “administered orally” NCT04728711 ↗ |